Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Strong Buy

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Alkermes Inc. plc (ALKS)

Pharmaceutical Preparations

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

CONNAUGHT HOUSE, 1 BURLINGTON ROAD
DUBLIN 4, L2

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/16/1991

Market Cap

4,502,023,120

Shares Outstanding

166,880,000

Weighted SO

166,881,286

Total Employees

N/A

Upcoming Earnings

07/24/2024

Beta

0.4370

Last Div

0.0000

Range

22.01-32.88

Chg

0.3600

Avg Vol

1962320

Mkt Cap

4502023120

Exch

NASDAQ

Country

IE

Phone

353 1 772 8000

DCF Diff

4.7573

DCF

22.6077

Div Yield

0.0000

P/S

2.9856

EV Multiple

14.3009

P/FV

3.5840

Div Yield %

0.0000

P/E

15.9388

PEG

1.3847

Payout

0.1135

Current Ratio

2.9914

Quick Ratio

2.6136

Cash Ratio

1.0380

DSO

89.5382

DIO

268.5996

Op Cycle

358.1377

DPO

144.4814

CCC

213.6564

Gross Margin

0.8245

Op Margin

0.1669

Pretax Margin

0.1786

Net Margin

0.1915

Eff Tax Rate

-0.2696

ROA

0.1308

ROE

0.2266

ROCE

0.1488

NI/EBT

1.0721

EBT/EBIT

1.0701

EBIT/Rev

0.1669

Debt Ratio

0.1339

D/E

0.2301

LT Debt/Cap

0.1824

Total Debt/Cap

0.1871

Int Coverage

20.8233

CF/Debt

1.2661

Equity Multi

1.7187

Rec Turnover

4.0765

Pay Turnover

2.5263

Inv Turnover

1.3589

FA Turnover

4.8544

Asset Turnover

0.6833

OCF/Share

2.2224

FCF/Share

1.9436

Cash/Share

5.2050

OCF/Sales

0.2481

FCF/OCF

0.8745

CF Coverage

1.2661

ST Coverage

41.5325

CapEx Coverage

7.9701

Div&CapEx Cov

4.6931

P/BV

3.5840

P/B

3.5840

P/S

2.9856

P/E

15.9388

P/FCF

13.7615

P/OCF

12.3018

P/CF

12.3018

PEG

1.3847

P/S

2.9856

EV Multiple

14.3009

P/FV

3.5840

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 12, 18:15 Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know Benzinga Jan 02, 13:00 Decoding 5 Analyst Evaluations For Alkermes MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know Zacks Investment Research Dec 22, 18:15 Alkermes (ALKS) Outperforms Broader Market: What You Need to Know

Revenue Product Segmentation